We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

200 hedge funds and large institutions have $3.48B invested in Pacira BioSciences in 2014 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 73 increasing their positions, 77 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more call options, than puts

Call options by funds: $20.6M | Put options by funds: $12.9M

5% less repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 77

4% less funds holding

Funds holding: 208 → 200 (-8)

8% less capital invested

Capital invested by funds: $3.76B → $3.48B (-$285M)

11% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 36

56% less funds holding in top 10

Funds holding in top 10: 9 → 4 (-5)

Holders
200
Holders Change
-8
Holders Change %
-3.85%
% of All Funds
5.33%
Holding in Top 10
4
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-55.56%
% of All Funds
0.11%
New
32
Increased
73
Reduced
77
Closed
36
Calls
$20.6M
Puts
$12.9M
Net Calls
+$7.64M
Net Calls Change
+$12.6M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$56.6M
2
Invesco
Invesco
Georgia
+$44.1M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$37.5M
4
MCMC
Matrix Capital Management Company
New Hampshire
+$33.1M
5
American Century Companies
American Century Companies
Missouri
+$29.1M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$71.2M
2
1832 Asset Management
1832 Asset Management
Ontario, Canada
-$59.9M
3
CCI
Columbus Circle Investors
-$40.6M
4
Two Sigma Investments
Two Sigma Investments
New York
-$22.2M
5
NCGI
Next Century Growth Investors
Minnesota
-$19.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
101
EAM Investors
California
$1.83M +$221K +2,340 +13%
CPIM
102
Columbia Partners Investment Management
Virginia
$1.79M -$966K -10,212 -34%
GH
103
GAM Holding
Switzerland
$1.77M +$1.89M +20,000 New
DekaBank Deutsche Girozentrale
104
DekaBank Deutsche Girozentrale
Germany
$1.75M -$166K -1,750 -8%
ICRM
105
Insight Capital Research & Management
California
$1.73M -$5.63M -59,477 -75%
SI
106
Stephens Inc
Arkansas
$1.71M +$67.3K +711 +4%
PPA
107
Parametric Portfolio Associates
Washington
$1.71M -$119K -1,262 -6%
First Trust Advisors
108
First Trust Advisors
Illinois
$1.7M -$14.1K -149 -0.8%
UBS Group
109
UBS Group
Switzerland
$1.7M +$1.81M +19,167 New
VFA
110
Virtus Fund Advisers
Connecticut
$1.69M +$8.7K +92 +0.5%
AQR Capital Management
111
AQR Capital Management
Connecticut
$1.54M -$3.97M -41,994 -71%
AI
112
Axiom Investors
Connecticut
$1.54M -$765K -8,084 -32%
Franklin Resources
113
Franklin Resources
California
$1.47M +$1.57M +16,609 New
SAM
114
Security Asset Management
New York
$1.46M +$1.56M +16,462 New
WMSA
115
Weiss Multi-Strategy Advisers
New York
$1.42M +$378K +4,000 +33%
Barclays
116
Barclays
United Kingdom
$1.37M +$153K +1,621 +12%
SI
117
Standard Investments
New York
$1.35M +$900K +9,520 +166%
Federated Hermes
118
Federated Hermes
Pennsylvania
$1.34M – – –
TAM
119
Tocqueville Asset Management
New York
$1.2M +$1.28M +13,500 New
EAM
120
Eventide Asset Management
Massachusetts
$1.18M – – –
D.E. Shaw & Co
121
D.E. Shaw & Co
New York
$1.16M +$1.24M +13,122 New
CC
122
Curian Capital
Colorado
$1.15M -$43.3K -458 -3%
M&T Bank
123
M&T Bank
New York
$888K -$161K -1,701 -15%
Renaissance Technologies
124
Renaissance Technologies
New York
$869K -$2.84M -30,000 -75%
PP
125
PDT Partners
New York
$860K +$180K +1,900 +24%
3 4
5
6 7

PCRX Hedge Fund Activity: Q4 2014 in Review

200 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2014, worth a combined $3.48B — down 7.6% from $3.76B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of PCRX and 32 opened new positions — a net loss of 4 holders — while 77 trimmed existing stakes and 73 added.

The largest buyer was Jennison Associates, adding an estimated $56.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $71.2M.

  • 200 institutional investors held Pacira BioSciences (PCRX) as of Q4 2014, down from 208 in Q3 2014.
  • Funds reported $3.48B of Pacira BioSciences stock for Q4 2014, down 7.6% quarter-over-quarter.
  • 32 funds opened new Pacira BioSciences positions in Q4 2014 and 36 closed out, a net change of -4 holders.
  • The largest Pacira BioSciences buyer in Q4 2014 was Jennison Associates, an estimated $56.6M added.
  • The largest Pacira BioSciences seller in Q4 2014 was T. Rowe Price Associates, an estimated $71.2M sold.

Based on aggregated 13F filings for Q4 2014.